Overview

Markers of Osteoporosis in Cystic Fibrosis

Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.
Phase:
Phase 4
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Denosumab